LIST OF REPORTS
SCIENCE AND TECHNOLOGY COMMITTEE REPORTS
IN THE CURRENT PARLIAMENT
Session 1997-98
First Report: The Implications of the Dearing Report
for the Structure and Funding of University Research (HC 303)
Second Report: The Year 2000—Computer Compliance (HC 342)
Third Report: Glaxo Wellcome and SmithKline Beecham: The Merger
Proposals (HC 627)
Fourth Report: The Cloning of Animals from Adult Cells (HC 1039)
Fifth Report: British Biotech (HC 888)
Sixth Report: Science and the Comprehensive Spending Review (HC
1040)
First Special Report: The Government's Response to the Committee's
Fourth Report, Session 1996-97, The Research Council System: Issues
for the Future (HC 302)
Second Special Report: The Government's Response to the Committee's
Third Report, Session 1996-97, The Natural Environment Research
Council and Research into Climate Change (HC 306)
Third Special Report: The Government's Response to the Committee's
First Report, Session 1997-98, The Implications of the Dearing
Report for the Structure and Funding of University Research (HC
799)
Fourth Special Report: The Government's Response to the Committee's
Fifth Report, Session 1997-98, British Biotech (HC 1185)
Session 1998-99
First Report: The Scientific Advisory System: Genetically
Modified Foods (HC 286)
Second Report: The National Endowment for Science, Technology
and the Arts (HC 472)
Third Report: The Scientific Advisory System: Mobile Phones and
Health (HC 489)
Fourth Report: The Regulation of the Biotechnology Industry (HC
535)
First Special Report: The Government's Response to the Committee's
Sixth Report, Session 1997-98, Science and the Comprehensive Spending
Review (HC 234)
Second Special Report: The Government's Response to the Committee's
Second Report, The National Endowment for Science, Technology
and the Arts (HC 822)
Session 1999-2000
First Report: The Year 2000—Computer Compliance:
Follow-Up (HC 37)
Second Report: Engineering and Physical Sciences Based Innovation
(HC 195-I)
Third Report: Scientific Advisory System: Diabetes and Driving
Licences (HC 206-I)
Fourth Report: Glaxo Wellcome and SmithKline Beecham (HC 207-I)
Fifth Report: Government Expenditure on Research and Development:
The Forward Look (HC 196-I)
Sixth Report: Cancer Research—A Fresh Look (HC 332-I)
Seventh Report: The Government's Expenditure on Research and Development:
The Forward Look—The Government's Reply (HC 723)
First Special Report: Government Response to the Committee's Second
Report, Engineering and Physical Sciences Based Innovation (HC
451)
Second Special Report: Joint Working with the Lords Science and
Technology Committee
(HC 980)
Third Special Report: Government Response to the Seventh Report
of the Science and Technology Committee on the Government's Expenditure
on Research and Development: The Forward Look—The Government's
Reply (HC 981)
Session 2000-2001
First Report: EQUAL (Extend Quality Life) (HC 43)
Second Report: Corus plc—Research and Development (HC
110)
Third Report: Scientific Advisory System: Scientific Advice on
Climate Change (HC 14)
Fourth Report: The Scientific Advisory System (HC 257)
Fifth Report: Genetics and Insurance (HC 174)
Sixth Report: Are We Realising Our Potential? (HC 200)
First Special Report: The Work of the Science and Technology Committee
1997-2000
(HC 44)
Second Special Report: The Government's Response to the Science
and Technology Committee's First Report on EQUAL (Extend Quality
Life) (HC 386)
| 
